文献速递骨质疏松与代谢性骨病小儿骨科

特立帕肽治疗杜氏肌营养不良患者严重骨质疏松的安全性与疗效

Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy.
PubMed 文献 · Osteoporos Int · 2020-07-17

这项前瞻性研究纳入6例长期使用糖皮质激素、尽管接受双膦酸盐治疗仍存在严重骨质疏松的杜氏肌营养不良患者,给予特立帕肽20微克每日皮下注射1–2年。骨健康(骨折、椎体形态测量和双能X线吸收测定)保持稳定,无不良事件;长骨骨折率似乎下降,但骨密度和骨含量变化轨迹与治疗前无差异。作者认为需进一步研究以更好理解特立帕肽在该人群中的疗效。

要点

  • 6例杜氏肌营养不良合并严重骨质疏松患者接受特立帕肽20微克每日皮下注射1–2年,骨健康保持稳定且无不良事件。
  • 椎体高度和Genant骨折分级保持稳定,长骨骨折率似乎从0.84/年降至0.09/年。
  • 骨密度和骨含量变化轨迹在特立帕肽治疗前后无差异,P1NP升高而实验室安全指标保持稳定。

核心结论

  • 在6例因杜氏肌营养不良合并严重骨质疏松而接受特立帕肽治疗的患者中,观察到骨健康稳定、P1NP适度升高,且无安全性担忧。
  • 作者认为需进一步研究以更好理解特立帕肽治疗杜氏肌营养不良患者骨质疏松的疗效。

研究设计与样本

  • 前瞻性治疗6例杜氏肌营养不良合并严重骨质疏松的青少年和年轻成人患者,特立帕肽20微克每日皮下注射,疗程1–2年。
  • 纳入标准为长期糖皮质激素治疗,且尽管接受双膦酸盐治疗仍存在严重骨质疏松,或对双膦酸盐不耐受。
  • 检查长骨和椎体骨折结局,包括椎体形态测量、骨密度和骨含量、骨形成标志物、安全性指标及不良事件。

主要发现

  • 特立帕肽开始治疗时平均年龄17.9岁(范围13.9–22.1岁)。
  • 全部6例患者每日使用糖皮质激素(平均±标准差;疗程10.9±2.5年),5例不能行走。
  • 5例患者曾接受双膦酸盐治疗7.9±4.2年。
  • 基线时全部患者存在椎体骨折和长骨脆性骨折史。
  • 椎体高度和Genant骨折分级保持稳定;长骨骨折率似乎下降(从0.84/年降至0.09/年);1例患者在治疗6个月时发生长骨骨折。

关键数值与推荐

  • 特立帕肽剂量为20微克每日皮下注射,疗程1–2年。
  • 骨密度和骨含量变化轨迹在特立帕肽治疗前后无差异。
  • P1NP升高,而实验室安全指标保持稳定且无担忧。
  • 未观察到不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 样本量为6例患者。
  • 作者认为需进一步研究以更好理解特立帕肽治疗杜氏肌营养不良患者骨质疏松的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Osteoporosis is a major concern in patients with Duchenne muscular dystrophy. In this novel study of teriparatide treatment in 6 patients with severe osteoporosis, bone health (fractures, vertebral morphometry, and DXA) remained stable, with no adverse events. These findings will help inform future osteoporosis research in this challenging population. INTRODUCTION: Despite standard therapy with vitamin D and bisphosphonates (BP), many patients with Duchenne muscular dystrophy (DMD) continue to sustain fragility fractures due to long-term glucocorticoid treatment and limited mobility. We aimed to evaluate the safety and efficacy of teriparatide for the treatment of severe osteoporosis in adolescent and young adult patients with DMD. METHODS: We prospectively treated 6 patients with DMD who had severe osteoporosis with teriparatide 20 mcg subcutaneously daily for 1-2 years. Inclusion criteria were long-term glucocorticoid therapy, and severe osteoporosis despite treatment with BP, or intolerance to BP. We examined long bone and vertebral fracture outcomes, including vertebral morphometry measures, bone mineral density and content, bone formation markers, safety indices, and adverse events. RESULTS: The mean age at teriparatide start was 17.9 years (range 13.9-22.1 years). All 6 patients were on daily glucocorticoids (mean ± SD; duration 10.9 ± 2.5 years) and 5 were non-ambulatory. Five patients had been treated with BP for 7.9 ± 4.2 years. All had vertebral and a history of long bone fragility fractures at baseline. Vertebral heights and Genant fracture grading remained stable. Long bone fracture rate appeared to decrease (from 0.84/year to 0.09/year); one patient sustained a long bone fracture at 6 months of treatment. Trajectories for change in bone mineral density and content were not different post- vs. pre-teriparatide. Procollagen type 1 amino-terminal propeptide (P1NP) increased, while laboratory safety indices remained stable and non-concerning. No adverse events were observed. CONCLUSION: In six patients with DMD treated with teriparatide for severe osteoporosis, we observed stable bone health and modest increases in P1NP, without safety concerns. Further studies are needed to better understand teriparatide efficacy for treatment of osteoporosis in patients with DMD.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Nasomyont N, Keefe C, Tian C, et al. Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy. Osteoporos Int. 2020. PMID: 32676823. doi:10.1007/s00198-020-05549-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。